Kaerus Bioscience
Pre-clinicalKaerus is turning scientific advances into treatment realities for patients with Fragile X syndrome and related genetic syndromes of neurodevelopment.
Founded
2021
Focus
Small Molecules
About
Kaerus is turning scientific advances into treatment realities for patients with Fragile X syndrome and related genetic syndromes of neurodevelopment.
Funding History
1Total raised: $2.8M
Seed$2.8MUndisclosedApr 15, 2022
Company Info
TypePrivate
Founded2021
LocationCambridge, United Kingdom
StagePre-clinical
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile